12 results about "Placental cell" patented technology

One major aspect of the invention relates to a cell composition comprising a population of engineered mucosa-related constant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.

This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.

This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.

To provide an improved porcine scaffold comprising decellularized porcine placental extracellular matrix. Further provided are methods of preparing the improved decellularized porcine placental extracellular matrix as well as methods of treatment.SOLUTION: Provided are porcine scaffolds comprising a decellularized porcine placental extracellular matrix, wherein the porcine scaffold comprises at least about 0.5% w / w hyaluronic acid based on the total weight of the porcine scaffold, and methods of preparing the porcine scaffolds.SELECTED DRAWING: Figure 9

Provided herein are cells or populations of cells comprising a polynucleotide encoding a cleavage resistant CD16 polypeptide. Also provided herein are methods of suppressing the proliferation of tumor cells such as HER2+ and methods of treating cancers, such as HER2+ in a subject with populations of placental-derived natural killer cells or placental-derived T cells comprising a cleavage resistant CD16. The natural killer cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The placental-derived T cells can be isolated from cord blood or from placental perfusate.

The application discloses a kind of based on HAPLN1 down-regulation induced preeclampsia animal model construction method and application of placental cell abnormal aging, belong to the field of biological medicine technology.The application can stably induce the animal model with typical preeclampsia clinical characteristics by reducing the expression level of HAPLN1 in pregnant mice, while reproducing the abnormal phenotype of placental cell aging.The method has strong controllability in operation process, and the model has good reproducibility, which can provide effective experimental tools for in-depth study of the pathogenesis of preeclampsia and development of new diagnosis and treatment strategies.

The invention is directed to a composition of soluble placental ECM in storage solution and the methods of manufacture related thereto. The solubilized placental ECM solution is manufactured through a process of partitioning placental ECM from the placental tissue in a high acidic pH environment and performing an ultrafiltration step and diafiltration step through a tangential flow filtration system to increase the pH. The soluble placental ECM retains the native characteristics of placental ECM components and includes collagens (types I, III, V, VI, IX, and X), elastin, laminin, and fibronectin.

This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.

This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

The invention belongs to the technical field of biology, and discloses anti-cracking cream containing sheep placenta cell extract and a preparation process of the anti-cracking cream. Through an optimized raw material treatment process, a composite enzymolysis technology, a formula synergistic interaction and a quality control system, active small molecule peptides in sheep placentas are efficiently extracted, and a stable and uniform emulsion product is prepared by adopting a proper emulsification process, so that the skin antioxidant, moisturizing and anti-cracking repairing effects are remarkably improved.

This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

The invention discloses a micro-fluidic chip device for functional research of a placenta bile acid transporter, and relates to the technical field of research of placenta cell bile acid transporters, the micro-fluidic chip device comprises a table body, four corners of the bottom of the table body are provided with pillars; the bracket is fixed at the top of the table body, and a plurality of chip mechanisms are arranged at the top of the bracket; and the plurality of conveying assemblies are fixed at the top of the table body at equal intervals, and the plurality of conveying assemblies are in one-to-one correspondence with the plurality of chip mechanisms. Through work of the power assembly, the transmission mechanism and the pneumatic assembly, the first pistons in the first barrel and the second barrel can ascend and descend, and then placenta cells can reciprocate in the chip mechanism, so that the placenta cells make full contact with the two faces of a biological membrane of the chip mechanism, and the placenta cells can be separated from the chip mechanism. Therefore, the cell culture efficiency is improved, and the overall experiment efficiency is further improved.